

AD \_\_\_\_\_

**GRANT NO:**

DAMD17-94-J-4152

**TITLE:**

Development of Anti-Idiotypic Monoclonal Antibodies for the Treatment of Breast Cancer

**PRINCIPAL INVESTIGATOR:**

Malaya Chatterjee, Ph.D.  
Amanda Sherratt, M.D., Ph.D.

**CONTRACTING ORGANIZATION:**


University of Kentucky  
Lucille P. Markey Cancer Center  
Lexington, Kentucky 40506-0057

**REPORT DATE:**

15 May 95

**TYPE OF REPORT:**

Annual



**PREPARED FOR:** U.S. Army Medical Research and Materiel  
Command  
Fort Detrick, Maryland 21702-5012

**DISTRIBUTION STATEMENT:** Approved for public release;  
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

19950706 014

DTIC QUALITY INSPECTED 5

# REPORT DOCUMENTATION PAGE

Form Approved  
OMB No. 0704-0188

1. AGENCY USE ONLY (Leave blank) 2. REPORT DATE 3. REPORT TYPE AND DATES COVERED  
May 15, 1995 Annual July 1, 1994-June 30, 1995

4. TITLE AND SUBTITLE  
Development of Anti-idiotypic Monoclonal Antibodies for the Treatment of Breast Cancer

5. FUNDING NUMBERS  
DAMD17-94-J-4152

6. AUTHOR(S)  
P.I. Malaya Chatterjee, Ph.D.  
Research Fellow: Amanda Sherratt, M.D., Ph.D.

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)  
University of Kentucky  
Lucille P. Markey Cancer Center  
201 Kinkead Hall  
Lexington, Kentucky 40506-0057

8. PERFORMING ORGANIZATION  
REPORT NUMBER

9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES)  
U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

10. SPONSORING/MONITORING  
AGENCY REPORT NUMBER

11. SUPPLEMENTARY NOTES  
None

12a. DISTRIBUTION/AVAILABILITY STATEMENT  
Approved for public release; distribution unlimited

12b. DISTRIBUTION CODE

## 13. ABSTRACT (Maximum 200 words)

For the development of HER2/neu anti-idiotypic antibodies, groups of female BALB/c mice were immunized with three sets of monoclonal antibodies (Ab1), designated 520C9, 741F8 and 454C11, directed at distinct antigenic determinants of HER2/neu. Hybridomas were generated from each treatment group by fusing spleen cells from immunized mice with non-secretory mouse myeloma cells. One, stable Ab2 producing hybrid each of 520C9 and 741F8 were obtained, and cloned twice by limiting dilution. The isotypes of 520C9 and 741F8 Ab2's were IgG1k by ELISA. 520C9 and 741F8 Ab2 cells were used to produce mouse ascites and the Ab2 purified by affinity chromatography and confirmed by SDS-PAGE. A competitive binding assay using Ab2, Ab1 and the human breast cancer cell line SK-BR-3 (which express HER2/neu on their cell surface), showed that 50µl of each of 520C9 and 741F8 Ab2 containing supernatants inhibited the binding of Ab1 to SK-BR-3 cells by ~80%. Polyclonal anti-anti-idiotypic antibodies (Ab3), were generated in rabbits and mice using purified 520C9 Ab2. Immunocytochemistry studies showed poor binding of 520C9 Ab3 sera to SK-BR-3 cells as compared to Ab1 indicating that this Ab3 was unable to recognize HER2/neu.

DTIC QUALITY INSPECTED 5

14. SUBJECT TERMS  
Breast Cancer, Hybridomas  
Monoclonal anti-idiotypic antibodies

15. NUMBER OF PAGES  
16  
16. PRICE CODE

17. SECURITY CLASSIFICATION  
OF REPORT

Unclassified

18. SECURITY CLASSIFICATION  
OF THIS PAGE

Unclassified

19. SECURITY CLASSIFICATION  
OF ABSTRACT

Unclassified

20. LIMITATION OF ABSTRACT

Unlimited

## GENERAL INSTRUCTIONS FOR COMPLETING SF 298

The Report Documentation Page (RDP) is used in announcing and cataloging reports. It is important that this information be consistent with the rest of the report, particularly the cover and title page. Instructions for filling in each block of the form follow. It is important to **stay within the lines** to meet optical scanning requirements.

**Block 1. Agency Use Only (Leave blank).**

**Block 2. Report Date.** Full publication date including day, month, and year, if available (e.g. 1 Jan 88). Must cite at least the year.

**Block 3. Type of Report and Dates Covered.** State whether report is interim, final, etc. If applicable, enter inclusive report dates (e.g. 10 Jun 87 - 30 Jun 88).

**Block 4. Title and Subtitle.** A title is taken from the part of the report that provides the most meaningful and complete information. When a report is prepared in more than one volume, repeat the primary title, add volume number, and include subtitle for the specific volume. On classified documents enter the title classification in parentheses.

**Block 5. Funding Numbers.** To include contract and grant numbers; may include program element number(s), project number(s), task number(s), and work unit number(s). Use the following labels:

<b>C</b> - Contract	<b>PR</b> - Project
<b>G</b> - Grant	<b>TA</b> - Task
<b>PE</b> - Program Element	<b>WU</b> - Work Unit Accession No.

**Block 6. Author(s).** Name(s) of person(s) responsible for writing the report, performing the research, or credited with the content of the report. If editor or compiler, this should follow the name(s).

**Block 7. Performing Organization Name(s) and Address(es).** Self-explanatory.

**Block 8. Performing Organization Report Number.** Enter the unique alphanumeric report number(s) assigned by the organization performing the report.

**Block 9. Sponsoring/Monitoring Agency Name(s) and Address(es).** Self-explanatory.

**Block 10. Sponsoring/Monitoring Agency Report Number.** (If known)

**Block 11. Supplementary Notes.** Enter information not included elsewhere such as: Prepared in cooperation with...; Trans. of...; To be published in... When a report is revised, include a statement whether the new report supersedes or supplements the older report.

**Block 12a. Distribution/Availability Statement.** Denotes public availability or limitations. Cite any availability to the public. Enter additional limitations or special markings in all capitals (e.g. NOFORN, REL, ITAR).

**DOD** - See DoDD 5230.24, "Distribution Statements on Technical Documents."

**DOE** - See authorities.

**NASA** - See Handbook NHB 2200.2.

**NTIS** - Leave blank.

**Block 12b. Distribution Code.**

**DOD** - Leave blank.

**DOE** - Enter DOE distribution categories from the Standard Distribution for Unclassified Scientific and Technical Reports.

**NASA** - Leave blank.

**NTIS** - Leave blank.

**Block 13. Abstract.** Include a brief (*Maximum 200 words*) factual summary of the most significant information contained in the report.

**Block 14. Subject Terms.** Keywords or phrases identifying major subjects in the report.

**Block 15. Number of Pages.** Enter the total number of pages.

**Block 16. Price Code.** Enter appropriate price code (*NTIS only*).

**Blocks 17. - 19. Security Classifications.** Self-explanatory. Enter U.S. Security Classification in accordance with U.S. Security Regulations (i.e., UNCLASSIFIED). If form contains classified information, stamp classification on the top and bottom of the page.

**Block 20. Limitation of Abstract.** This block must be completed to assign a limitation to the abstract. Enter either UL (unlimited) or SAR (same as report). An entry in this block is necessary if the abstract is to be limited. If blank, the abstract is assumed to be unlimited.

## FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

( ) Where copyrighted material is quoted, permission has been obtained to use such material

( ) Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

( ) Citations of commercial organizations and trade names in this report do not constitute an official Department of the Army endorsement or approval of the products or services of these organizations.

*MC* (X) In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources, National Research Council (NIH Publication No. 86-23, Revised 1985

( ) For the protection of human subjects, the investigator(s) have adhered to policies of applicable Federal Law 45 CFR 46.

( ) In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

Malaya Chatterjee  
Principal Investigator's Signature

May 15, 1995  
Date

<b>Accession For</b>	
NTIS GRA&I	<input checked="checked" type="checkbox"/>
DTIC TAB	<input type="checkbox"/>
Unannounced	<input type="checkbox"/>
Justification	
By	
Distribution/	
Availability Codes	
Dist	Avail and/or Special
A-1	

ATTACHMENT 7

## TABLE OF CONTENTS

	Page
Introduction	1
Body	2
Conclusions	8
References	10

## INTRODUCTION

Breast cancer is a major cause of cancer deaths in women. The incidence of breast cancer has steadily increased over the last two decades and patients with recurrent disease are not curable by standard therapies. In human breast cancer, amplification and overexpression of the cell membrane protein HER2/neu, which is not present on normal breast tissue, has been observed to occur in a significant number of tumors. In 189 primary human breast cancers, HER2/neu was found to be amplified from 2 to over 20 fold in 30% of the tumors (1). Patients with multiple copies of the HER2/neu gene in DNA from their tumors had a shorter time to relapse as well as a shorter overall survival (1-3), indicating that HER2/neu gene amplification was prognostic for both disease behavior and clinical outcome in these patients. Not only were increased copy numbers of HER2/neu in breast cancers related to a poorer prognosis, but gene amplification of HER2/neu correlated with lymph node involvement (1-5), histological grade (5,6), negative estrogen receptor content (7,8), early recurrence (4,7), increased mitotic activity (9), all of which are considered to be poor prognostic indicators. In a retrospective study, the expression of HER2/neu determined immunohistochemically in positive breast cancer samples from 253 patients found that HER2/neu positive breast cancers behaved more aggressively in the first 2-3 years following diagnosis (10). Several studies have shown that overexpression of HER2/neu occurs in as many as 15-40% of breast cancers and that overexpression of HER2/neu is associated with poor survival (1-3). Therefore HER2/neu present on the surface of overexpressing breast cancer cells offers a good target for immunotherapy. It has been shown that monoclonal antibodies raised against the human protein that bind to the extracellular domain of HER2/neu can inhibit the growth of tumor cells *in vitro* (11-13) and *in vivo* (14). A recent report has determined that breast cancer specific cytotoxic T lymphocytes recognize a 9 amino acid peptide from the transmembrane portion of the HER2/neu protein (15).

Since cancer patients are often immunosuppressed and also tolerant to some tumor-associated antigens such as HER2/neu, triggering an active immune response to such antigens represents a challenge in cancer therapy. One approach has been to use tumor derived material as the immunogen. As an alternative to the use of tumor antigens or tumor cells, the network hypothesis of Neils Jerne (16) offers a different approach to vaccine therapy using the so-called internal image antigens (17-21). According to the network concept, immunization with a given antigen will generate the production of antibodies against this antigen termed Ab1. This Ab1 can generate a series of anti-idiotypic antibodies termed Ab2. Some of these Ab2

molecules can effectively mimic the three dimensional structures of external antigens. These particular anti-idiotypes called Ab2 $\beta$ , which fit into the paratopes of Ab1, can induce specific immune responses similar to the nominal antigen. Anti-idiotypic antibodies of the  $\beta$  type express the internal image of the antigen recognized by the Ab1 antibody and can be used as surrogate antigens. Immunization with Ab2B can lead to the generation of anti-anti-idiotypic antibodies (Ab3) that recognize the corresponding original antigen. Indeed, human trials using anti-idiotypic monoclonal antibodies (Ab2 $\beta$ ) to stimulate immunity against the patients own tumor has shown promising results. Objective clinical improvement has been observed in patients with colorectal cancer, melanoma and T-cell lymphoma ( for reviews see 22,23).

Our overall aim has been to apply this approach to the treatment of breast cancer by attempting to develop monoclonal anti-idiotypic antibodies against HER2/neu starting with a series of mouse monoclonal antibodies (Ab1) that recognize different epitopes of HER2/neu (24-26). We selected 3 monoclonal antibodies 520C9, 741F8 and 454C11 which recognize distinct antigenic determinants on HER2/neu. These monoclonal antibodies appear highly selective; immunoperoxidase staining of normal human tissues showed negligible staining with these antibodies (26 ). Furthermore, when conjugated to ricin A, these antibodies produced immunotoxins selectively cytotoxic to SK-BR-3 breast cancer cells (26). The restricted specificity of these monoclonal antibodies together with their high binding capacity to a representative breast carcinoma cell line SK-BR-3, make them excellent target for generating Ab2 hybridomas. The use of various Ab2 that mimic multiple epitopes on the tumor cell surface may increase immunotherapeutic efficacy of Ab2 immunizations. Furthermore, the internal image antigens (Ab2) generated against these 3 monoclonal antibodies may cover almost all of breast tumors expressing HER2/neu and in many cases will complement each other. Our overall goal is to develop monoclonal anti-idiotypic antibodies as a surrogate for the tumor associated antigen HER2/neu to be used for the treatment of breast cancer.

## BODY

### Materials and Methods

#### *Animals*

Female BALB/c mice, 6-8 weeks old and male New Zealand rabbits 4-6 months old from Harlan Laboratories.

#### *Cells*

Established human cell lines were obtained from the American Type Culture Collection (Rockville, MD). SK-BR-3 cells were cultured in McCoy's Medium and HBL 100 cells cultured in RPMI 1640 each supplemented with 10% fetal calf serum.

#### *Antibody*

Mouse monoclonal antibodies 520C9, 741F8 and 454C11 were obtained from Chiron Corp. These antibodies were used to immunize female BALB/c mice for the production of anti-idiotypic antibodies. Ascites of Ab2 hybridomas was prepared by injecting pristane-primed BALB/c mice with  $2 \times 10^6$  to  $1 \times 10^7$  viable cells into the peritoneal cavity. The IgG fraction was isolated from ascites using a Hi-Trap Protein G affinity column (Pharmacia, Piscataway, NJ). The purity of the isolated IgG was assessed by SDS-PAGE (10% mini-gel) (27-29).

#### *Immunization of BALB/c mice*

Groups of BALB/c mice, 6-8 weeks old were immunized with monoclonal antibodies 520C9, 741F8 or 454C11 (Ab1's). The first injection was administered i.p. with 100 $\mu$ g of Ab1 mixed with Freund's complete adjuvant. The second injection was administered s.c. two weeks later with 100 $\mu$ g of Ab1 in Freund's incomplete adjuvant. Subsequent injections were given i.p. at two week intervals, with 100 $\mu$ g of Ab1 coupled to KLH. Mice were bled two weeks following each injection and the sera checked for anti-idiotypic activity by Sandwich RIA using the respective Ab1. Mouse IgG1 was used as control. Three days prior to the fusion, mice were boosted with Ab1 (100 $\mu$ g in PBS) injected intravenously into the tail vein.

#### *Coupling of antibody with keyhole limpet hemocyanin (KLH)*

Antibody stock solution (1mg/ml) was mixed with KLH (1mg/ml) in PBS in the presence of glutaraldehyde (0.05%). The mixture was rotated for 2 hours at room temperature and then dialyzed for 24 hours against PBS in the cold (27).

#### *Fusion*

Fusion of BALB/c mouse spleen cells with non-secretory P3-653 myeloma cells using 50% polyethyleneglycol (3,400 mwt. Aldrich Chemical Co., Milwaukee, WI) was carried out as previously described (27-29). Hybrids were selected using hypoxanthine-aminopterin-thymidine media.

#### *Selection of anti-idiotypic antibodies (Ab2)*

Initial screening of hybridomas for anti-idiotypic antibody production was done by Sandwich RIA using the respective Ab1 at a concentration of 250 ng/well to coat plates (27,28). After overnight incubation at 4°C, plates were blocked with 1% bovine serum albumin in PBS for 30



minutes. Thereafter, 50  $\mu$ l of undiluted hybridoma culture supernatants were incubated for 2 hours at room temperature with continuous shaking. After washing with PBS, plates were further incubated for 2 hours at room temperature with ~50,000 cpm of I-125-radiolabelled Ab1. Stable Ab2 producing fusion wells were then further checked for reactivity toward an unrelated mouse monoclonal Ab1, mouse IgG1 and KLH by Sandwich RIA as described above. Ab2 producing fusion wells were expanded in hypoxanthine-thymidine media and cloned twice by limited dilution to obtain a single population of Ab2 producing cells using monolayers of mouse peritoneal macrophages as feeder cells (27,28).

#### *Isotype determination*

The Ig isotype of the cloned Ab2 producing hybridomas was determined by ELISA. Essentially, ELISA plates were coated with goat-anti-mouse immunoglobulins (250ng/well) that specifically bind mouse immunoglobulins (Cappel, Westchester, PA). After overnight incubation at 4°C, plates were blocked with 2% bovine serum albumin in PBS containing 0.05% Tween 20 for 2 hours. Thereafter, 50 $\mu$ l of undiluted hybridoma culture supernatant were added in triplicate and incubated for 2 hours at room temperature with gentle shaking. After washing with PBS containing 0.05% Tween 20, plates were incubated for 2 hours with specific alkaline phosphatase labelled anti-mouse immunoglobulins (against IgG1, IgG2a, IgG2b, IgG3, IgM, IgA, kappa chain, lambda chain). Plates were washed and p-nitrophenolphosphate in diethanolamine buffer added to each well (50 $\mu$ l of 1mg/ml) and the color change read in an ELISA reader at 10, 20 and 60 minutes at 405nm (28,29).

#### *Immunization of animals with anti-idiotypic antibodies (Ab2)*

Once Ab2 were identified they were injected into BALB/c mice as previously described (27,28). Male New Zealand rabbits were injected s.c. with 500 $\mu$ g of purified Ab2 in Freund's complete adjuvant on day 0 and the same amount of Ab2 in Freund's incomplete adjuvant on day 14, followed by two i.m. booster injections in PBS during the next 2 months (27,28). Animals were bled periodically and the sera checked for anti-Ab2 activity by Sandwich RIA using plates coated with purified Ab2 (250ng/well).

#### *Cell binding assays*

##### *(1). Radioimmunoassay (RIA)*

This assay was performed in disposable microfold 96-well microfilter plates. The plate was first treated with 10% fetal calf serum and 1% bovine serum albumin in PBS. Then, 50 $\mu$ l or 100 $\mu$ l aliquots of Ab2 culture supernatants were added to individual wells containing  $5 \times 10^5$  viable SK BR 3 cells (in 50 $\mu$ l PBS). Ab1 (~50,000 cpm in 50 $\mu$ l PBS)

was then added to each well and the plate shaken for 2 hours at room temperature. After incubation, the plate was washed 3 times with PBS containing 10% bovine serum albumin with suction. The radioactivity in the washed filter paper was measured in a gamma counter (Packard Instruments).

## (2). Immune flow cytometry

Binding of Ab3 to tumor cell lines was also determined by immune flow cytometry. Antigen positive SK-BR-3 cells ( $1 \times 10^6$ /well) were reacted with Ab1 (520C9) and Ab3 in a volume of 100  $\mu$ l at 4°C for 1 hour. After washing, the cells were incubated with either goat-anti-mouse F(ab')<sub>2</sub> IgG-FITC labelled antibody or goat-anti-rabbit IgG-FITC labelled antibody (Tago Inc. Burlingame, CA) for 30 minutes at 4°C. The cells were washed twice, fixed in 2% paraformaldehyde and analyzed by immune flow cytometry (FACS STAR, Becton Dickinson). Antigen negative HBL 100 human breast cells were used as a control in this assay.

## Results

### *Generation of monoclonal anti-idiotypic hybridomas*

The Ab1's 520C9, 741F8 and 454C11 were used to generate Ab2 in BALB/c mice. Seven immunizations with 520C9, five immunizations with 741F8 and three immunizations with 454C11 were required to generate a sufficient Ab2 response in BALB/c mice for fusions. That is, a 1:160 dilution of immune sera produced more than double that of pre-immune sera in binding to the respective Ab1 by Sandwich RIA. Furthermore, immune sera exhibited no binding to KLH or mouse IgG. Culture supernatants of primary fusion cells were initially screened on the basis of their binding to the respective Ab1 and their failure to bind to mouse IgG1, KLH or another unrelated mouse monoclonal Ab1 (mAb 8019). Only one stable Ab2 producing hybridoma was obtained for each of 520C9 and 741F8 from approximately 800 fusion wells and 400 fusion wells screened for Ab2 activity respectively. These Ab2 hybridomas were cloned twice by limited dilution. No Ab2 producing hybridomas were obtained for 454C11 of the ~300 fusion wells screened for Ab2 binding. This work constitutes the goals of **Specific Aim #1 parts a,b and c** of the original proposal.

### *Competitive binding of Ab1, Ab2 and SK-BR-3 cells*

A preliminary study was conducted to determine whether 520C9 Ab2 and 741F8 Ab2 would compete for the binding of a fixed amount of Ab1 (~100,000 cpm) to SK-BR-3 cells, which express the tumor antigen HER2/neu (Figure 1). As little as 50  $\mu$ l of culture supernatant inhibited the binding of radiolabelled Ab1 to SK-BR-3 cells by ~80%. This work was the goal of **Specific Aim #2a** of the original proposal.




Figure 1. Inhibition of 520C9 and 741F8 binding to SK-BR-3 cells by Ab2 containing hybridoma supernatants.

Viable SK-BR-3 cells ( $2-3 \times 10^6$ ) were plated in disposable microfold 96 well chamber microfilter plates and reacted with different amounts of Ab2 containing culture supernatants and a fixed amount of I-125 Ab1 (100,000 cpm). Values are the mean  $\pm$  SE of 3 determinations. 1= SK-BR-3 cells + I-125-Ab1 (520C9 or 741F8). 2= SK-BR-3 cells + I-125-Ab1 + mouse Immune sera (1/20 dilution). 3 and 4= SK-BR-3 cells + I-125-Ab1 + hybridoma supernatant (50 $\mu$ l and 100 $\mu$ l respectively).

#### Purification of Ab2

Next, 520C9 and 741F8 Ab2 producing hybridomas were used to produce mouse ascites (a rich source of Ab2), and the Ab2 purified by Hi-Trap Protein G affinity chromatography (Figure 2). SDS-PAGE (10% mini-gel) shows 2 bands of approximate molecular weight 25,000 and 50,000 which correspond to the molecular weights of mouse IgG light and heavy chains respectively. This work was part of the goal of **Specific Aim #1** of the original proposal so that purified Ab2 could then be used for further characterization studies.




Figure 2. SDS-PAGE of 520C9 and 741F8 Ab2's purified from mouse ascites using a Hi-Trap Protein G column.

Lane 1= Column eluent containing ~2 $\mu$ g purified protein. Lane 2= Mouse IgG (2 $\mu$ g, Sigma Chemical Co. St Louis MO). Lane 3= Molecular weight markers (10 $\mu$ l, BioRad Labs., Hercules CA).

#### *Isotype determination*

The IgG isotypes of 520C9 and 741F8 Ab2's in culture supernatant were determined by ELISA to be IgG1k. This experiment was the goal of **Specific Aim #2a** as part of Ab2 characterization.

#### *Specificity of Ab2*

To determine whether the anti-520C9 antibodies were specific for the Ab1 and not directed against allotype determinants, we set up a Sandwich RIA in which plates were coated with 250ng of mouse IgG1 or an unrelated mouse monoclonal antibody (8019, IgG1k), and then incubated them with 50µl of Ab2 hybridoma supernatant. The binding of Ab2 to the proteins on the plate was measured using radiolabelled Ab1. Less than 300 cpm bound to plates coated with mouse IgG1 or mAb 8019 reacted with Ab2 hybridoma supernatant, whereas 1,500-4,000 cpm bound to 520C9 coated plates reacted with Ab2 hybridoma supernatant. These experiments were the goal of **Specific Aim #2a** in characterizing further the Ab2 obtained.

#### *Generation of polyclonal Ab3*

If the Ab2 are true internal images, then they should induce the production of antigen specific Ab3 in the absence of exposure to antigen in a genetically unrestricted way and across species barriers (22, 23). To determine this, we immunized BALB/c mice and rabbits with 520C9 Ab2 for the production of Ab3 that might share idiotopes with Ab1 and exhibit identical binding specificity. Fourteen days following the third immunization, sera from rabbits and mice immunized with Ab2 showed significant immunity assessed by the binding of dilutions of sera to plates coated with Ab2. These studies were the goal of **Specific Aim #2b**.

#### *Comparison of the binding of Ab1 and Ab3 mouse and rabbit sera to tumor antigen*

To ascertain whether these Ab3 are directed against the tumor associated antigen HER2/neu, the binding of mouse and rabbit Ab3 sera to human SK-BR-3 cells which express the antigen and to a control human breast cell line HBL 100 which do not express this antigen were determined by immunofluorescence (Figure 3). Neither mouse or rabbit Ab3 sera tested were able to selectively bind to SK-BR-3 cells (Figure 3).




Figure 3. Binding of Ab3 sera from mouse and rabbit immunized with 520C9 Ab2 with SK-BR-3 and HBL 100 cells determined by immunofluorescence. 1= Cells only. 2= Cells + second antibody (anti-mouse or anti-rabbit FITC). 3,4,5= Cells + pre-immune sera (1/50, 1/100 and 1/500 dilution respectively). 6,7,8= Cells + immune sera (1/50, 1/100 and 1/500 dilution respectively). 9= Positive control consisting of cells + mouse Ab1 (520C9, 40 $\mu$ g).

### CONCLUSIONS

The Ab1's 520C9 and 741F8 were used to generate Ab2's in female BALB/c mice (**Task #1 of the original proposal**). Despite a high fusion frequency, only one stable Ab2 producing hybridoma was obtained for each of 520C9 and 741F8 which were then cloned twice by limited dilution to obtain a single population of Ab2 producing cells (**Task #1 of the original proposal**). Despite several fusions with 454C11, no Ab2 producing hybridomas have been obtained for this Ab1. Currently another fusion is in progress with 454C11 in an attempt to generate stable Ab2 producing clones from this Ab1. Future work will be directed toward obtaining more Ab2 producing hybrids from all of these Ab1's.

A preliminary study was conducted to determine whether 520C9 and 741F8 Ab2's in hybridoma culture supernatants exhibited high competitive binding with their respective Ab1's to SK-BR-3 cells; a breast cancer cell line which expresses the antigen HER2/neu to a high degree on its cell surface (**Task #2 of the original proposal**). We found that 50 $\mu$ l of each of the Ab2 containing culture supernatants inhibited the binding of Ab1 to SK-BR-3 cells by approximately 80% (Figure 1). Furthermore, the specificity of 520C9 and 741F8 binding (determined by Sandwich RIA), was directed only to their respective Ab1's as no binding was observed to mouse IgG, KLH or to other unrelated mouse monoclonal antibodies we have in our laboratory (mAb8019/11D10).

520C9 Ab2 and 741F8 Ab2 were then purified by affinity chromatography (Figure 2), and their isotypes determined to be IgG1k by ELISA. Using purified 520C9 Ab2 we determined whether this Ab2 was able to induce the production of antigen specific Ab3 in another group of mice and in another species which we chose to be rabbit (**Task #2 of the original proposal**). Although both mice and rabbits showed significant immunity i.e. Ab3 response (assessed by the binding of sera to plates coated with Ab2 in a Sandwich assay), 520C9 Ab3 mouse or rabbit sera was unable to compete with 520C9 Ab1 for the binding to SK-BR-3 cells in an immunofluorescence assay (Figure 3). This 520C9 Ab2 would not appear to have potential for use in humans as a treatment for breast cancer. We are in the process of conducting comprehensive specificity experiments with purified Ab2 of 741F8 together with *in vivo* experiments in which mice and rabbits are injected with 741F8 Ab2 to generate an Ab3 response (**Task#2 of the original proposal**).

## REFERENCES

1. Slamon, D., Clark, G., Wong, S., Levin, W., Ullrich, A. and McGuire, W. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. *Science* 235:177-182, 1987.
2. Wright, C., Angus, B., Nicholson, S., Sainsbury, R., Cairns, J., Gullick, W., Icely, P., Harris, A. and Wilson Horn, C. Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. *Cancer Res.* 49:2087-2090, 1989.
3. Slamon, D., Godolphin, W., Jones, L., Iltis, J., Wong, S., Keith, D., Levin, W., Stuart, S., Udove, J., Ullrich, A. and Press, M. Studies of the HER2/neu proto-oncogene in human breast and ovarian cancer. *Science* 244:707-712, 1989.
4. Zhou, D., Battifora, H., Yokota, J., Yamamoto, T. and Cline, M. Association of multiple copies of the erb-B-2 oncogene with spread of breast cancer. *Cancer Res.* 47:6123-6125, 1987.
5. Tavassoli, M., Quirke, P., Farzaneh, F., Lock, N., Mayne, L. and Kirkham, N. C-erbB-2/c-erbA co-amplification indicative of lymph node metastasis and c-myc amplification of high tumor grade, in human breast carcinoma. *Br. J. Cancer* 60:505-510, 1989.
6. Berger, M., Locher, G., Saurer, S., Gullick, W., Waterfield, M., Groner, B. and Hynes, N. Correlation of c-erb-B2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. *Cancer Res.* 48:1238-1243, 1988.
7. Cline, M., Battifora, H. and Yokota, J. Protooncogene abnormalities in human breast cancer: correlation with anatomic features and clinical course of disease. *Clin. Oncol.* 7:999, 1987.
8. Guerin, M., Gabillot, M., Mathieu, M., Travagli, J., Spielmann, M., Andrieu, N. and Riou, G. Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer: prognostic significance. *Int. J. Cancer* 43:201-208, 1989.
9. Heintz, N., Leslie, K., Rogers, L. and Howard, P. Amplification of the c-erbB-2 oncogene and prognosis of breast adenocarcinomas. *Arch. Path. Lab. Med.* 114:160-163, 1990.
10. Schroeter, C., DePolter, C., Rathsmann, K., Willighagen, R. and Greys, J. C-erbB-2 positive breast tumors behave more aggressively in the first years after diagnosis. *Br. J. Cancer*, 66:728-734, 1992.
11. Hudziak, R., Lewis, G., Wingert, M., Fendly, B., Shepard, M. and Ullrich, A. p185 HER-2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. *Mol. Cell. Biol.* 9:1165-1172, 1989.
12. Tagliabue, E., Centis, F., Campiglio, M., Mastroianni, A., Martignone, S., Pellegrini, R., Casalini, P., Lallzi, C., Menard, S. and Colnaghi, M. Selection of monoclonal antibodies which induce

- internalization and phosphorylation of p185 HER-2 and growth inhibition of cells with HER-2/neu gene amplification. *Int. J. Cancer*, 47:933-937, 1991.
13. Bacus, S., Stancovski, I., Huberman, E., Chin, D., Hurwitz, E., Mills, Ullrich, A., Sela, M. and Yarden, Y. Tumor-inhibitory monoclonal antibodies to the HER-2/neu receptor induce differentiation of human breast cancer cells. *Cancer Res.* 52:2580-2589, 1992.
  14. Drebin, J., Link, V. and Greene, M. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo. *Oncogene*, 2:387-394, 1988.
  15. Peoples, G.E., Goedegebuure, P.S., Smith, R., Linehan, D.C., Yoshino, I. and Eberlein, T.J. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER/2neu-derived peptide. *Proc. Natl. Acad. Sci. USA* 92:432-436, 1995.
  16. Jerne, N.K. Towards a network theory of the immune system. *Ann. Immunol. (Paris)* 125C:373-389, 1974.
  17. Nisonoff A. and Lamoyi, E., Implications of the presence of an internal image of the antigen in anti-idiotypic antibodies: possible application to vaccine production. *Clin. Immunol. Immunopathol.* 21, 397-406, 1981.
  18. Kohler, H. The immune network revisited. In: *Idiotypic Antibodies in Biology and Medicine* edited by H. Kohler, J. Urbain, and P. Cazenave, New York: Academic Press, 1985, 3-28.
  19. Kohler, H., Muller, S., and Bona, C. Internal antigen and the immune network. *Proc. Soc. Exp. Biol. Med.* 178:189-193, 1985.
  20. Jeme, N.K., Roland, J., and Cazenave, A. Recurrent idiotypes and internal images. *EMBO J.* 1:243-248, 1982.
  21. Bona, C.A. and Kohler, H. Anti-idiotypic antibodies and internal images. In: *Probes for Receptor Structure and Function*. Vol. 4, edited by J.C. Venter, C.M. Fraser, and J. Lindstrom, New York: Alan R. Liss, 1984, 141-150.
  22. Bhattacharya-Chatterjee, M., Foon, K.A. and Kohler, H. Anti-idiotypic monoclonal antibodies as vaccines for human cancer. *Inter. Rev. Immunol.* 7:289-302, 1991.
  23. Bhattacharya-Chatterjee, M., Foon, K.A. and Kohler, H. Anti-idiotypic approaches to cancer therapy. *Contemporary Oncology*, 2:27-36, 1992.
  24. Bjorn, M.J., Ring, D., and Frankel, A. Evaluation of monoclonal antibodies for the development of breast cancer immunotoxins. *Cancer Research* 45:1214-1221, 1985.
  25. Frankel, A.E., Ring, D.B., Tringale, F., and Hsieh-Ma, S.: Tissue distribution of breast cancer-associated antigens defined by monoclonal antibodies. *J. Biol. Response Modifiers* 4:273-286, 1985.
  26. Ring, D.B., Kassel, J.A., Hsieh-Ma, S.T., Bjorn, M.J., Tringale, F., Eaton, A.M., Reid, S.A., Frankel, A.E., and Nadji, M.



Distribution and physical properties of BCA200, a Mr 2000,000 glycoprotein selectively associated with human breast cancer. *Cancer Res.* 49:3070-3080, 1989.

27. Bhattacharya-Chatterjee, M., Pride, M., Seon, B. and Kohler, H. Idiotypic vaccines against human T cell acute lymphoblastic leukemia. I. Generation and characterization of biologically active monoclonal anti-idiotopes. *J. Immunol.* 139:1354-1360, 1987.
28. Bhattacharya-Chatterjee M., Chatterjee, S., Biddle, W., Foon, K and Kohler, H. Idiotypic vaccines against human T cell leukemia. *J. Immunol.* 141:1398-1403, 1988.
29. Bhattacharya-Chatterjee, M., Mukerjee, S., Biddle, W., Foon. K. and Kohler, H. Murine monoclonal anti-idiotypic antibody as a potential network antigen for human carcinoembryonic antigen. *J. Immunol.* 145:2758-2765, 1990.